GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) represent the most significant advance in obesity pharmacotherapy in decades, with clinical trials showing BMI reductions of 4 to 6 points.